News

A 27-year experiment comparing organic and conventional soil management indicates that animal-based composts do not promote pathogen survival and may help to reduce the spread of foodborne disease.

Researchers have developed novel hydrogels to effectively target drugs to specific tumor sites in response to temperature and pH changes within the tumor microenvironment.

A new study has found that direct human alterations to natural aquatic ecosystems can increase methane emissions.

A natural brilliant blue coloring has been discovered. The new cyan blue, obtained from red cabbage, could be an alternative to synthetic blue food colorings such as the widely used FD&C Blue No. 1.

Pfizer's oral antiviral clinical candidate PF-07321332, a SARS-CoV2-3CL protease inhibitor, is progressing to Phase 1 testing following preclinical testing demonstrating potent in vitro anti-viral activity against SARS-CoV-2.

Scientists and archaeologists have found the first evidence of a religious diet locked inside pottery fragments excavated from the early medieval Jewish community of Oxford.

A study has revealed how T cells in the small intestine respond to bile acids, offering localized treatment direction for a cause of chronic illness.

A clinical trial is underway to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech COVID-19 vaccines.

A new study suggests that most people in high-income countries generally support the donation of some of their nation’s COVID-19 vaccine supplies to low-income countries.

The UK rollout of the Moderna COVID-19 vaccine – known as mRNA-1273 – has commenced today in Carmarthen, Wales. mRNA-1273 is the third COVID-19 vaccine to be authorized for human use in the UK. It joins Oxford–AstraZeneca's ChAdOx1 vaccine and Pfizer–BioNTech's BNT162b2 vaccine as part of the country's large-scale vaccination program.